Key result
In patients with severe ischaemia on dipyridamole stress CMR, CMR-related revascularisation reduced the risk of MACE compared to no revascularisation (11% vs 39%; effect size 0.2, 95% CI 0.1-0.7, P=0.01).
Why the study?
Does CMR-related revascularisation reduce major adverse cardiac events in patients with ischaemic chest pain stratified by dipyridamole stress CMR?
Cohort (n=601)
No
Does CMR-related revascularisation reduce major adverse cardiac events in patients with ischaemic chest pain stratified by dipyridamole stress CMR?
Dipyridamole stress CMR effectively stratifies risk in patients with suspected CAD, identifying a high-risk subgroup with both perfusion deficits and wall motion abnormalities that significantly benefits from revascularisation.
OBJECTIVE: To determine the prognostic and therapeutic implications of stress perfusion cardiovascular magnetic resonance (CMR) on the basis of the ischaemic cascade. SETTING: Single centre study in a teaching hospital in Spain. PATIENTS: Dipyridamole stress CMR was performed on 601 patients with ischaemic chest pain and known or suspected coronary artery disease. On the basis of the ischaemic cascade, patients were categorised in C1 (no evidence of ischaemia, n = 354), C2 (isolated perfusion deficit at stress first-pass perfusion imaging, n = 181) and C3 (simultaneous perfusion deficit and inducible wall motion abnormalities, n = 66). CMR-related revascularisation (n = 102, 17%) was defined as the procedure prompted by the CMR results and carried out within the next three months. RESULTS: During a median follow-up of 553 days, 69 major adverse cardiac events (MACE), including 21 cardiac deaths, 14 non-fatal myocardial infarctions and 34 admissions for unstable angina with documented abnormal angiography were detected. In non-revascularised patients (n = 499), the MACE rate was 4% (14/340) in C1, 20% (26/128) in C2 and 39% (12/31) in C3 (adjusted p value = 0.004 vs C2 and <0.001 vs C1). CMR-related revascularisation had neutral effects in C2 (20% vs 19%, 1.1 (0.5 to 2.4), p = 0.7) but independently reduced the risk of MACE in C3 (39% vs 11%, 0.2 (0.1 to 0.7), p = 0.01). CONCLUSIONS: Dypiridamole stress CMR is able to stratify risk on the basis of the ischaemic cascade. A small group of patients with severe ischaemia-simultaneous perfusion deficit and inducible wall motion abnormalities-are at the highest risk and benefit most from MACE reduction due to revascularisation.
No takes yet. Share an insight, caveat, or question.
Bodı́ et al. (2008) conducted a cohort in Ischaemic chest pain and known or suspected coronary artery disease (n=601). CMR-related revascularisation vs. No CMR-related revascularisation was evaluated on Major adverse cardiac events (MACE) (0.2, 95% CI 0.1 to 0.7, p=0.01). In patients with severe ischaemia on dipyridamole stress CMR, CMR-related revascularisation reduced the risk of MACE compared to no revascularisation (11% vs 39%; effect size 0.2, 95% CI 0.1-0.7, P=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: